glp-1 drugs ro is now selling Foundayo, a second daily oral alternative to injectable therapies Ro launches GLP-1 supply tracker

[DOI] [PMC free article] [PubMed] [Google Scholar] 131.Tang S.T., Zhang Q., Tang H.Q., Wang C.J., Su H., Zhou Q

The clinical trial investigators estimated that in an ideal scenario where participants take the pill every day as prescribed, weight loss would be 16.6 percentwhich is similar to results seen with injectable Wegovy

Beyond these well-documented medical risks, a significant proportion of individuals with obesity present with psychiatric comorbidities, most notably depression and anxiety disorders [4], as well as eating disorders such as binge eating disorder (BED) [5]

Due to their preclinical testing and lack of comparison with other dual receptor agonists such as tirzepatide, further studies are needed to determine whether the effects of these unimolecular compounds are superior to those of clinically tested drugs

Lin JS, Bowles EJA, Williams SB, et al